T-cell Therapy-Mediated Myocarditis Secondary to Cytokine Release Syndrome

Chimeric antigen receptor (CAR) T-cell therapy is expanding to a wider patient population; however, cytokine release syndrome (CRS) is the most important adverse event of these therapies. Patients suffering from high-grade CRS also develop signs of cardiac dysfunction and frequently manifest vascula...

Descripción completa

Detalles Bibliográficos
Autores principales: Afzal, Anoshia, Farooque, Umar, Gillies, Elizabeth, Hassell, Lewis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515743/
https://www.ncbi.nlm.nih.gov/pubmed/32983717
http://dx.doi.org/10.7759/cureus.10022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515743/
https://www.ncbi.nlm.nih.gov/pubmed/32983717
http://dx.doi.org/10.7759/cureus.10022

Ejemplares similares